Sign Up Today and Learn More About Cygnal Therapeutics Stock
Invest in or calculate the value of your shares in Cygnal Therapeutics or other pre-IPO companies through EquityZen's platform.
Cygnal Therapeutics Stock (CYTH)
Cygnal Therapeutics is a biotechnology company
About Cygnal Therapeutics Stock
Founded
2016
Headquarters
Cambridge, MA, US
Industries
Software, Data and Analytics, Artificial Intelligence
Cygnal Therapeutics is developing drugs to manipulate Exoneural Biology for the treatment of cancer, immunological diseases, and regenerative processes. Powered by a comprehensive, cutting-edge neurotechnology platform, They are discovering new dimensions of neural function. Cygnal was founded by Flagship Pioneering in the VentureLabs innovation foundry.
Cygnal Therapeutics Press Mentions
Stay in the know about the latest news on Cygnal Therapeutics
CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism ...
aacrjournals • Dec 20, 2023
BeiGene founder honored at BWB - BioProcess
bioprocessintl • Dec 20, 2023
http://www.prnewswire.com/news-releases/cygnal-therapeutics-named-to-chemical--engineering-news-10-start-ups-to-watch-list-301172960.html
zpr • Nov 16, 2020
Cygnal Therapeutics nabs Merck, Takeda vet Wagner for CMO
fiercebiotech • Sep 17, 2020
Cygnal Appoints Elaine Caughey as Chief Business Officer
zpr • May 29, 2020
Investors in Cygnal Therapeutics
Discover investors in Cygnal Therapeutics stock and explore their portfolio companies
Cygnal Therapeutics Management
Leadership team at Cygnal Therapeutics
Principal / Co-Founder, Flagship Pioneering / Cygnal Therapeutics
Jordi Mata-Fink
Partner / Founding President & CEO, Flagship Pioneering / Cygnal Therapeutics
Avak Kahvejian
Join now and verify your accreditation status to gain access to:
- Cygnal Therapeutics current valuation
- Cygnal Therapeutics stock price
- Available deals in Cygnal Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Cygnal Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Cygnal Therapeutics through EquityZen funds. These investments are made available by existing Cygnal Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Cygnal Therapeutics stock?
Shareholders can sell their Cygnal Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 320K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
